Article Text

other Versions

PDF
Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index
  1. Walter P Maksymowych (walter.maksymowych{at}ualberta.ca)
  1. University of Alberta, Canada
    1. Catherine Mallon
    1. University of Alberta, Canada
      1. Sharon Morrow
      1. Univesity of Alberta, Canada
        1. Kamran Shojania
        1. University of British Columbia, Canada
          1. Wojciech Olszynski
          1. University of Saskatchewan, Canada
            1. Robert L Wong
            1. Abbott Laboratories, United States
              1. John Sampalis
              1. McGill University, Canada
                1. Barbara Conner-Spady
                1. University of Alberta, Canada

                  Abstract

                  Background: Enthesitis is a recommended core domain for assessment of ankylosing spondylitis (AS), but no measurement has yet been validated according to Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) criteria.

                  Objective: Using data from two clinical studies of adalimumab, we sought to validate an enthesitis index for patients with AS according to OMERACT criteria.

                  Methods: We validated an enthesitis index in two AS patient cohorts; 1) a longitudinal cohort (n=223), and 2) 22 patients from three Canadian sites participating in a 24-week randomised placebo-controlled trial of adalimumab in AS. Construct validity was evaluated by correlation analysis with the BASDAI, BASFI, and quality of life instruments. Reproducibility was assessed by intra-class correlation coefficient (ICC), and responsiveness was assessed by Guyatt's effect size and standardised response mean.

                  Results: The most frequently affected sites were the greater trochanter and supraspinatus insertion (~20%). Patients with enthesitis had significantly greater scores for the BASDAI, BASFI, patient global, ASQOL, and SF-36 (p<0.0001). Enthesitis score contributed significantly to variance in the BASDAI and BASFI. Inter-observer ICCs were 0.96 in the longitudinal cohort and 0.89 and 0.77 in the adalimumab clinical trial cohort (for status and change score, respectively). Significant differences in change scores were evident for all patients after 24 weeks of adalimumab treatment, (p=0.04), this being more significant when a subset of the most commonly affected entheses were analyzed (p=0.01).

                  Conclusion: AS patients with enthesitis constitute a more severe subset of disease, and the SPARCC Enthesitis Index is feasible and reliable for measurement of this condition. Discrimination requires further study in larger trials.

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.